Practice Variation in Perioperative Dexamethasone Use and Outcomes in Brain Metastasis Resection
Authors: David Wasilewski, Tommaso Araceli, Artem Rafaelian, Matthias Demetz, Benedikt Asey, Tunc-Faik Ersoy, Alice Dauth, Anne Neumeister, Ricarda Peukert, Paul Pöser, Christopher Krämer, Jan Bukatz, Zoe Shaked, Claudius Jelgersma, Anton Früh, Ran Xu, Martin Misch, David Capper, Felix Ehret, Nikolaj Frost, Lars Bullinger, Ulrich Keilholz, Christian Senft, Leon Schmidt, Harald Krenzlin, Florian Ringel, Anne Pohrt, Hanno S. Meyer, Jens Gempt, Johannes Kerschbaumer, Christian Freyschlag, Claudius Thomé, Matthias Simon, Daniel Dubinski, Thomas Freiman, Nils Ole Schmidt, Martin Proescholdt, Peter Vajkoczy, Julia Onken
Journal: JAMA Network Open (2025)

Importance Variations in perioperative dexamethasone dosing are common in brain metastasis resection, but their impact on patient outcomes remains unclear. Objective To evaluate the association between perioperative dexamethasone dosing and patient outcomes, focusing on overall survival (OS) and progression-free survival (PFS). Design, Setting, and Participants This retrospective multicenter comparative effectiveness study used data collected from January 2010 to December 2023. Patients with symptomatic brain metastases undergoing primary surgical resection at 7 neurological centers in Germany and 1 in Austria and who had complete records of perioperative dexamethasone dosing were included. Propensity score matching (PSM) was used to control for confounders. Analysis was conducted from March to June 2024. Exposures Cumulative perioperative dexamethasone administration over 27 days, dichotomized at 122 mg using maximally selected rank statistics. Main Outcomes and Measures The primary outcome was OS. Secondary outcomes included extracranial PFS (ecPFS) and intracranial PFS (icPFS) as well as incidence of wound revision surgery after brain metastasis resection. Hazard ratios (HRs) were calculated using Cox proportional hazards models. Results A total of 1064 patients were included in the analysis. The median (IQR) age was 64 (56-72) years, with 489 female patients (49%) and 541 male patients (51%). Non–small cell lung cancer (NSCLC) was the most common tumor entity (564 patients [53%]), followed by breast cancer (146 patients [14%]) and melanoma (138 patients [13%]). After PSM, patients receiving cumulative dexamethasone doses less than 122 mg had a median OS of 19.1 (95% CI, 15.2-22.4) months compared with 12.0 (95% CI, 9.1-14.7) months for those receiving 122 mg or more ( P = .002). Multivariable analysis showed an independent association between higher cumulative dexamethasone doses and reduced OS (HR, 1.40; 95% CI, 1.18-1.66; P &amp;amp;lt; .001). Secondary analyses demonstrated consistent findings with icPFS and ecPFS and a dose-response association between cumulative dexamethasone and hazard for death. Conclusions and Relevance In this study, higher cumulative perioperative dexamethasone was associated with reduced OS, icPFS, and ecPFS in patients undergoing brain metastasis resection. These findings suggest that stricter dosing protocols could improve outcomes. Prospective trials are warranted to confirm these associations and guide evidence-based practice.